Pantoprazole Improves Glycemic Control in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial | Zendy

Pawan Kumar Singh | Zendy; Debasish Hota | Zendy; Pinaki Dutta | Zendy; Naresh Sachdeva | Zendy; Amitava Chakrabarti | Zendy; Anand Srinivasan | Zendy; Inderjeet Singh | Zendy; Anil Bhansali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pantoprazole Improves Glycemic Control in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Author(s) -

Pawan Kumar Singh,

Debasish Hota,

Pinaki Dutta,

Naresh Sachdeva,

Amitava Chakrabarti,

Anand Srinivasan,

Inderjeet Singh,

Anil Bhansali

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-1720

Subject(s) - pantoprazole , medicine , glycemic , insulin , endocrinology , gastrin , glucose homeostasis , type 2 diabetes , placebo , diabetes mellitus , proton pump inhibitor , gastroenterology , insulin resistance , omeprazole , alternative medicine , pathology , secretion

Proton pump inhibitors, by elevating plasma gastrin, can influence glucose-insulin homeostasis. Because there are no controlled clinical trials, the present study was planned to evaluate the effect of pantoprazole, a proton pump inhibitor, on glucose-insulin homeostasis in patients with type 2 diabetes (T2DM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research